[HTML][HTML] Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa
S Eichstadt, M Barriga, A Ponakala, C Teng… - JCI insight, 2019 - ncbi.nlm.nih.gov
S Eichstadt, M Barriga, A Ponakala, C Teng, NT Nguyen, Z Siprashvili, J Nazaroff, ES Gorell…
JCI insight, 2019•ncbi.nlm.nih.govBACKGROUND Recessive dystrophic epidermolysis bullosa (RDEB) patients have
mutations in the COL7A1 gene and thus lack functional type VII collagen (C7) protein; they
have marked skin fragility and blistering. This single-center phase 1/2a open-label study
evaluated the long-term efficacy, safety, and patient-reported outcomes in RDEB patients
treated with gene-corrected autologous cell therapy. METHODS Autologous keratinocytes
were isolated from participant skin biopsies. Epidermal sheets were prepared from cells …
mutations in the COL7A1 gene and thus lack functional type VII collagen (C7) protein; they
have marked skin fragility and blistering. This single-center phase 1/2a open-label study
evaluated the long-term efficacy, safety, and patient-reported outcomes in RDEB patients
treated with gene-corrected autologous cell therapy. METHODS Autologous keratinocytes
were isolated from participant skin biopsies. Epidermal sheets were prepared from cells …
Abstract
BACKGROUND
Recessive dystrophic epidermolysis bullosa (RDEB) patients have mutations in the COL7A1 gene and thus lack functional type VII collagen (C7) protein; they have marked skin fragility and blistering. This single-center phase 1/2a open-label study evaluated the long-term efficacy, safety, and patient-reported outcomes in RDEB patients treated with gene-corrected autologous cell therapy.
METHODS
Autologous keratinocytes were isolated from participant skin biopsies. Epidermal sheets were prepared from cells transduced with a retrovirus carrying the full-length human COL7A1 gene. These gene-corrected autologous epidermal sheets measured 5× 7 cm (35 cm 2) and were transplanted onto 6 wound sites in each of 7 adult participants (n= 42 sites total) from 2013 to 2017. Participants were followed for 2 to 5 years.
RESULTS
No participants experienced any serious related adverse events. Wound healing of 50% or greater by Investigator Global Assessment was present in 95%(36 of 38) of treated wounds versus 0%(0 of 6) of untreated control wounds at 6 months (P< 0.0001). At year 1, 68%(26 of 38) of treated wounds had 50% or greater healing compared with 17%(1 of 6) of control wounds (P= 0.025). At year 2, 71%(27 of 38) of treated wounds had 50% or greater healing compared with 17%(1 of 6) of control wounds (P= 0.019).
CONCLUSION
C7 expression persisted up to 2 years after treatment in 2 participants. Treated wounds with 50% or greater healing demonstrated improvement in patient-reported pain, itch, and wound durability. This study provides additional data to support the clinically meaningful benefit of treating chronic RDEB wounds with ex vivo, C7 gene–corrected autologous cell therapy. This approach was safe and promoted wound healing that was associated with improved patient-reported outcomes.
ncbi.nlm.nih.gov